Fuertes, Melody A.

HRN: 22-59-91  Sex: Female

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
01/02/2025
CLINDAMYCIN 150MG/ML, 4ML (AMP)
01/02/2025
01/22/2025
IVT
600mg
Q8
DM Foot Left, Wagner Grade IV, T/c Osteomyelitis Left Foot
Waiting Final Action 
01/02/2025
CEFTAZIDIME 1GM (VIAL)
01/02/2025
01/22/2025
IVT
2g
BID
DM Foot Left, Wagner Grade IV, T/c Osteomyelitis Left Foot
Waiting Final Action 
01/14/2025
AZITHROMYCIN 500MG TABLET (TAB)
01/14/2025
01/19/2025
ORAL
500mg
Od
Cough/crackles
Waiting Final Action 
01/14/2025
SILVER SULFADIAZINE 1%, 25G CREAM (TUBE)
01/14/2025
01/21/2025
TOPICAL
1%
OD
Dm Foot
Waiting Final Action 
01/14/2025
CEFTAZIDIME 1GM (VIAL)
01/14/2025
01/21/2025
IVTT
2g
Q8
Dm Foot With Gangrene
Waiting Final Action 
01/14/2025
CLINDAMYCIN 150MG/ML, 4ML (AMP)
01/14/2025
01/21/2025
IVTT
600mg
Q6
Dm Foot With Gangrene
Waiting Final Action 
01/17/2025
CLINDAMYCIN 150MG/ML, 4ML (AMP)
01/17/2025
01/24/2025
IVT
600 Mg
Q6h
DM Foot With Gangrene
Waiting Final Action 
01/17/2025
CEFTAZIDIME 1GM (VIAL)
01/17/2025
01/24/2025
IVTT
2 Gm
Q 8h
DM Foot With Gangrene
Waiting Final Action 
01/18/2025
PIPERACILLIN + TAZOBACTAM 4.5G (VLS)
01/18/2025
01/25/2025
IV
4.5gm
Q8
DM Foot
Waiting Final Action 

AMS Audit Form


Start Date: End Date:

Indication:

              

Type of Infection:

                             

           

Compliance to guidelines:



Initial appropriateness:



 If inappropriate:

           

Final appropriateness:



 If inappropriate:

              

Overall appropriateness: